FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3084151154> ?p ?o ?g. }

• W3084151154 endingPage "105" @default.
• W3084151154 startingPage "97" @default.
• W3084151154 abstract "Abstract Aim To assess the unrealized potential of glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) or sodium‐glucose co‐transport‐2 inhibitor (SGLT2i) use to reduce mortality in veterans with type 2 diabetes (T2D), coronary artery disease (CAD), and other characteristics congruent with clinical trial cohorts that established the efficacy of these agents. Methods Veterans with T2D and CAD on angiography in 2014 who were untreated with either a GLP‐1RA or a SGLT2i were assessed for key eligibility criteria of the LEADER (GLP‐1RA) and EMPA‐REG OUTCOME (SGLT2i) trials. Trial hazard ratios and 95% confidence intervals for all‐cause death were applied to deaths observed in veterans through 2018 to estimate the potential benefit of GLP‐1RA or SGLT2i use. Results Median observation was 4.3 years. Of 15 987 veterans with T2D and CAD, 1186 (7.4%) were excluded for GLP‐1RA or SGLT2i treatment, and 1386 lacked glycated haemoglobin measurement. Of the remaining 13 415 patients, 4103 (30.1%) and 5313 (39.6%) fulfilled the key criteria for the LEADER and EMPA‐REG OUTCOME trials, respectively. Death occurred in 1009 (24.6%) of LEADER‐eligible patients and 1335 (25.1%) of EMPA‐REG OUTCOME‐eligible patients. Under treatment with liraglutide in LEADER‐eligible veterans, a 3.5% (0.7%‐6.2%) potential absolute mortality reduction, corresponding to 144 (28‐253) fewer deaths (0.88 [0.17‐1.56] per 100 person‐years), might have been expected. Similarly, under treatment with empagliflozin in EMPA‐REG OUTCOME‐eligible veterans, a 7.9% (4.5%‐10.8%) potential absolute mortality reduction, corresponding to 418 (230‐573) fewer deaths (1.98 [1.14‐2.72] per 100 person‐years), might have been expected. Conclusions This analysis indicates unrealized opportunities to reduce mortality in selected veterans with T2D and CAD via increased GLP‐1RA and SGLT2i use." @default.
• W3084151154 created "2020-09-14" @default.
• W3084151154 creator A5000460998 @default.
• W3084151154 creator A5013111476 @default.
• W3084151154 creator A5013176551 @default.
• W3084151154 creator A5041608846 @default.
• W3084151154 creator A5043539190 @default.
• W3084151154 creator A5045470491 @default.
• W3084151154 creator A5050340607 @default.
• W3084151154 creator A5064675050 @default.
• W3084151154 creator A5065063579 @default.
• W3084151154 creator A5066767326 @default.
• W3084151154 creator A5078470996 @default.
• W3084151154 date "2020-10-03" @default.
• W3084151154 modified "2023-10-01" @default.
• W3084151154 title "Potential unrealized mortality benefit of glucagon‐like peptide‐1 receptor agonists and sodium‐glucose co‐transport‐2 inhibitors: A report from the Veterans Health Administration Clinical Assessment, Reporting and Tracking program" @default.
• W3084151154 cites W2016660427 @default.
• W3084151154 cites W2016704889 @default.
• W3084151154 cites W2033136851 @default.
• W3084151154 cites W2110333911 @default.
• W3084151154 cites W2146264128 @default.
• W3084151154 cites W2424539745 @default.
• W3084151154 cites W2425644022 @default.
• W3084151154 cites W2519510391 @default.
• W3084151154 cites W2626446274 @default.
• W3084151154 cites W2750917994 @default.
• W3084151154 cites W2754041380 @default.
• W3084151154 cites W2790249206 @default.
• W3084151154 cites W2806006824 @default.
• W3084151154 cites W2890465901 @default.
• W3084151154 cites W2894746763 @default.
• W3084151154 cites W2899521789 @default.
• W3084151154 cites W2899764361 @default.
• W3084151154 cites W2900236147 @default.
• W3084151154 cites W2900413769 @default.
• W3084151154 cites W2923028507 @default.
• W3084151154 cites W2923192703 @default.
• W3084151154 cites W2948612418 @default.
• W3084151154 cites W2954229159 @default.
• W3084151154 cites W2967013149 @default.
• W3084151154 cites W2968073288 @default.
• W3084151154 cites W2974260792 @default.
• W3084151154 cites W3005269555 @default.
• W3084151154 cites W4246340431 @default.
• W3084151154 doi "https://doi.org/10.1111/dom.14193" @default.
• W3084151154 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32902128" @default.
• W3084151154 hasPublicationYear "2020" @default.
• W3084151154 type Work @default.
• W3084151154 sameAs 3084151154 @default.
• W3084151154 citedByCount "1" @default.
• W3084151154 countsByYear W30841511542023 @default.
• W3084151154 crossrefType "journal-article" @default.
• W3084151154 hasAuthorship W3084151154A5000460998 @default.
• W3084151154 hasAuthorship W3084151154A5013111476 @default.
• W3084151154 hasAuthorship W3084151154A5013176551 @default.
• W3084151154 hasAuthorship W3084151154A5041608846 @default.
• W3084151154 hasAuthorship W3084151154A5043539190 @default.
• W3084151154 hasAuthorship W3084151154A5045470491 @default.
• W3084151154 hasAuthorship W3084151154A5050340607 @default.
• W3084151154 hasAuthorship W3084151154A5064675050 @default.
• W3084151154 hasAuthorship W3084151154A5065063579 @default.
• W3084151154 hasAuthorship W3084151154A5066767326 @default.
• W3084151154 hasAuthorship W3084151154A5078470996 @default.
• W3084151154 hasConcept C126322002 @default.
• W3084151154 hasConcept C134018914 @default.
• W3084151154 hasConcept C170493617 @default.
• W3084151154 hasConcept C185280430 @default.
• W3084151154 hasConcept C207103383 @default.
• W3084151154 hasConcept C2775887513 @default.
• W3084151154 hasConcept C2776398474 @default.
• W3084151154 hasConcept C2777180221 @default.
• W3084151154 hasConcept C2778938600 @default.
• W3084151154 hasConcept C2781308992 @default.
• W3084151154 hasConcept C44249647 @default.
• W3084151154 hasConcept C555293320 @default.
• W3084151154 hasConcept C71924100 @default.
• W3084151154 hasConceptScore W3084151154C126322002 @default.
• W3084151154 hasConceptScore W3084151154C134018914 @default.
• W3084151154 hasConceptScore W3084151154C170493617 @default.
• W3084151154 hasConceptScore W3084151154C185280430 @default.
• W3084151154 hasConceptScore W3084151154C207103383 @default.
• W3084151154 hasConceptScore W3084151154C2775887513 @default.
• W3084151154 hasConceptScore W3084151154C2776398474 @default.
• W3084151154 hasConceptScore W3084151154C2777180221 @default.
• W3084151154 hasConceptScore W3084151154C2778938600 @default.
• W3084151154 hasConceptScore W3084151154C2781308992 @default.
• W3084151154 hasConceptScore W3084151154C44249647 @default.
• W3084151154 hasConceptScore W3084151154C555293320 @default.
• W3084151154 hasConceptScore W3084151154C71924100 @default.
• W3084151154 hasIssue "1" @default.
• W3084151154 hasLocation W30841511541 @default.
• W3084151154 hasLocation W30841511542 @default.
• W3084151154 hasOpenAccess W3084151154 @default.
• W3084151154 hasPrimaryLocation W30841511541 @default.
• W3084151154 hasRelatedWork W2138965855 @default.
• W3084151154 hasRelatedWork W2169138798 @default.
• W3084151154 hasRelatedWork W2270921204 @default.
• W3084151154 hasRelatedWork W2403559169 @default.

• next